{"id":70729,"date":"2026-05-12T10:06:21","date_gmt":"2026-05-12T10:06:21","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70729"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"gdf-8","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/gdf-8\/","title":{"rendered":"GDF-8 (Miosstatina)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 GDF-8 (Miostatina)?<\/h3>\n<p style=\"margin: 0;\"><strong>GDF-8<\/strong> (Fator de Crescimento\/Diferencia\u00e7\u00e3o 8), tamb\u00e9m chamado <strong>miostatina<\/strong>, is a recombinant TGF-\u03b2 superfamily protein and the principal endogenous negative regulator of skeletal muscle mass. Loss-of-function mutations cause the well-known &#8220;double-muscling&#8221; phenotype in mice, cattle, dogs, and one documented human case. In published studies, recombinant GDF-8 is used as a pathway-stimulus tool: inducing atrophy phenotypes, validating myostatin antagonists such as <a href=\"https:\/\/medsbase.com\/pt-pt\/follistatin-344\/\">follistatina 344<\/a>, and characterising Smad2\/Smad3 downstream signalling. Supplied in 1\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">N\u00e3o formalmente registrada para o d\u00edmero maduro (prote\u00edna recombinante). Codificada pelo gene MSTN; UniProt O14793<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prote\u00edna recombinante (ligante da superfam\u00edlia TGF-\u03b2; d\u00edmero hom\u00f3logo maduro de 109 amino\u00e1cidos C-terminal ligado por dissulfeto, clivado de um precursor de 375 aa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~25,8 kDa (d\u00edmero hom\u00f3logo maduro; ~12,9 kDa por cadeia monom\u00e9rica)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estrutura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Mon\u00f3mero maduro de 109 aa com a estrutura can\u00f3nica de n\u00f3 de cistina da superfam\u00edlia TGF-\u03b2; dois mon\u00f3meros ligados covalentemente por uma liga\u00e7\u00e3o dissulfeto intermolecular para formar o d\u00edmero hom\u00f3logo biologicamente ativo; superf\u00edcies de liga\u00e7\u00e3o ao recetor envolvem ActRIIB<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prote\u00edna recombinante liofilizada (branca a branco-acinzentado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226595% (verificado por HPLC, COA dispon\u00edvel mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (frigor\u00edfico) para stock de trabalho; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar dentro de ~30 dias. Proteger da luz. N\u00e3o congelar-descongelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 as prote\u00ednas recombinantes s\u00e3o particularmente sens\u00edveis \u00e0 desnatura\u00e7\u00e3o por congela\u00e7\u00e3o-descongela\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para per\u00edodos de utiliza\u00e7\u00e3o mais curtos. Prote\u00edna transportadora (BSA, 0,1%) opcional para dilui\u00e7\u00f5es de trabalho, de modo a minimizar perdas por adsor\u00e7\u00e3o.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 GDF-8 (Miostatina)?<\/h2>\n<p><strong>GDF-8<\/strong> (Fator de Crescimento\/Diferencia\u00e7\u00e3o 8), comumente conhecida como <strong>miostatina<\/strong>, is a member of the transforming growth factor beta (TGF-\u03b2) superfamily and the principal physiological negative regulator of skeletal muscle mass. It was first characterised by McPherron, Lawler, and Lee (Nature 1997) as a secreted protein whose targeted disruption in mice produced animals with two- to three-fold greater skeletal muscle mass than wild-type controls. The same gene was rapidly identified as the cause of the &#8220;double-muscling&#8221; phenotype in Belgian Blue and Piedmontese cattle, the Bully Whippet phenotype in racing greyhounds, and one documented human case of striking infant hypermuscularity (Schuelke et al., NEJM 2004) \u2014 all carrying loss-of-function MSTN mutations. Mature myostatin is generated by post-translational processing of a 375-amino-acid preproprotein: the signal peptide is removed during secretion, then the prodomain (~243 aa) is cleaved off by furin proteases, releasing the active 109-amino-acid C-terminal mature myostatin. The active form is a homodimer of two mature monomer chains covalently linked by an intermolecular disulfide bond, with apparent mass approximately 25.8\u00a0kDa on non-reducing SDS-PAGE. The protein adopts the canonical TGF-\u03b2 cystine-knot fold and binds the activin type IIB receptor (ActRIIB) with high affinity to initiate Smad-mediated signalling. Recombinant GDF-8 is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Myostatin is <strong>aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Sinaliza\u00e7\u00e3o ActRIIB e o Eixo Smad2\/Smad3<\/h2>\n<p>O que torna o GDF-8 mecanicamente distinto entre os ligantes da superfam\u00edlia TGF-\u03b2 \u00e9 o seu <strong>papel dominante como um trav\u00e3o t\u00f3nico no crescimento muscular<\/strong> through a well-characterised three-step signalling cascade documented in published studies:<\/p>\n<ul>\n<li><strong>Liga\u00e7\u00e3o ao recetor ActRIIB e recrutamento do recetor tipo I<\/strong> \u2014 O homod\u00edmero de miostatina madura liga-se ao recetor de activina tipo IIB (ActRIIB) na superf\u00edcie das fibras musculares esquel\u00e9ticas e outros tipos celulares. O ActRIIB \u00e9 uma serina\/treonina quinase constitutivamente ativa que, uma vez ligada \u00e0 miostatina, recruta e trans-fosforila os recetores tipo I ALK4 (ActRIB) e ALK5 (T\u03b2RI). A estequiometria ligante-recetor \u00e9 um heterotetr\u00e2mero 2:2:2 no complexo ativo. A elimina\u00e7\u00e3o do ActRIIB produz um fen\u00f3tipo semelhante \u00e0 elimina\u00e7\u00e3o da miostatina, confirmando a identidade do recetor.<\/li>\n<li><strong>Fosforila\u00e7\u00e3o de Smad2\/Smad3 e transloca\u00e7\u00e3o nuclear<\/strong> \u2014 Os recetores tipo I ALK4\/ALK5 fosforilados fosforilam os Smads regulados pelo recetor \u2014 especificamente Smad2 e Smad3 na via da miostatina. O fosfo-Smad2\/Smad3 forma um complexo heterom\u00e9rico com Smad4 (Smad comum) e transloca para o n\u00facleo, onde se ligam a elementos de liga\u00e7\u00e3o Smad nos promotores de genes-alvo e recrutam cofatores transcricionais. A via Smad \u00e9 o principal resultado de sinaliza\u00e7\u00e3o para a miostatina no m\u00fasculo esquel\u00e9tico.<\/li>\n<li><strong>Efeitos transcricionais a jusante \u2014 upregula\u00e7\u00e3o de atrogin-1\/MuRF1 e supress\u00e3o da s\u00edntese proteica<\/strong> \u2014 O complexo Smad nuclear coordena um programa transcricional que promove a atrofia muscular atrav\u00e9s de tr\u00eas mecanismos convergentes: indu\u00e7\u00e3o dos atrogenes com atividade ubiquitina-ligase (atrogin-1\/Fbxo32 e MuRF1\/Trim63) para acelerar a degrada\u00e7\u00e3o proteica; inibi\u00e7\u00e3o da s\u00edntese proteica mediada por Akt\/mTOR atrav\u00e9s de comunica\u00e7\u00e3o cruzada com o eixo IGF\/insulina; e supress\u00e3o dos fatores reguladores miog\u00e9nicos (MyoD, miogenina) para retardar a repara\u00e7\u00e3o mediada por c\u00e9lulas sat\u00e9lite. O efeito l\u00edquido \u00e9 a redu\u00e7\u00e3o da acumula\u00e7\u00e3o de prote\u00edna muscular e, em doses elevadas ou exposi\u00e7\u00e3o cr\u00f3nica, atrofia franca.<\/li>\n<\/ul>\n<p>Importantly for studies design, GDF-8 acts as a tonic inhibitor under physiological conditions \u2014 muscle mass is regulated by the balance between myostatin tone (atrophic) and IGF\/Akt\/mTOR signalling (anabolic). This is why <a href=\"https:\/\/medsbase.com\/pt-pt\/follistatin-344\/\">Follistatina 344<\/a> (a myostatin\/activin antagonist) and recombinant GDF-8 (the agonist itself) are both used in muscle studies \u2014 the antagonist removes the brake, while the recombinant ligand is the experimental tool that quantifies how strong the brake is and validates antagonist activity in receptor-binding and reporter-cell assays. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Recombinant GDF-8 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Muscle atrophy and wasting studies<\/strong> \u2014 ensaios de atrofia in vitro de miotubos, prepara\u00e7\u00f5es musculares ex vivo, administra\u00e7\u00e3o in vivo para induzir fen\u00f3tipos de atrofia reprodut\u00edveis para estudo de estrat\u00e9gias de interven\u00e7\u00e3o (McPherron et al., Nature 1997; Lee, Annu Rev Cell Dev Biol 2004)<\/li>\n<li><strong>Valida\u00e7\u00e3o de antagonistas da miostatina<\/strong> \u2014 binding-affinity assays, neutralising-antibody potency assays, receptor-occupancy assays for drug discovery programmes targeting the myostatin pathway; canonical tool for validating <a href=\"https:\/\/medsbase.com\/pt-pt\/follistatin-344\/\">follistatina 344<\/a>, prote\u00ednas de fus\u00e3o sol\u00faveis ActRIIB-Fc e anticorpos anti-miostatina<\/li>\n<li><strong>Smad2\/Smad3 signalling pathway studies<\/strong> \u2014 cin\u00e9tica de fosforila\u00e7\u00e3o de Smad, imagem de transloca\u00e7\u00e3o nuclear, ensaios rep\u00f3rter de elementos de liga\u00e7\u00e3o a Smad, intera\u00e7\u00e3o com outros membros da via TGF-\u03b2<\/li>\n<li><strong>Atrogene transcription studies<\/strong> \u2014 an\u00e1lise do promotor de atrogina-1 (Fbxo32) e MuRF1 (Trim63), atividade do proteassoma ubiquitina, intera\u00e7\u00e3o com o eixo da autofagia<\/li>\n<li><strong>Modelos de caquexia e sarcopenia<\/strong> \u2014 modelos de caquexia em roedores com tumores, sarcopenia em ratos idosos, atrofia induzida por desnerva\u00e7\u00e3o \u2014 GDF-8 recombinante utilizado para amplificar ou recriar o fen\u00f3tipo de desgaste<\/li>\n<li><strong>Cardiac and other tissue studies<\/strong> \u2014 myostatin is expressed at lower levels in heart, adipose, and other tissues; published studies investigates GDF-8 effects in cardiomyocyte hypertrophy models and adipose-tissue biology<\/li>\n<li><strong>Comparative TGF-\u03b2 superfamily studies<\/strong> \u2014 compara\u00e7\u00e3o com o GDF-11, que est\u00e1 intimamente relacionado (90% de identidade de sequ\u00eancia no dom\u00ednio maduro) e com a activina A (que se liga ao mesmo sistema de recetores); dissec\u00e7\u00e3o mec\u00e2nica da seletividade dos recetores<\/li>\n<li><strong>Emparelhamento de farmacologia inversa com a Follistatina 344<\/strong> \u2014 coadministra\u00e7\u00e3o com <a href=\"https:\/\/medsbase.com\/pt-pt\/follistatin-344\/\">Follistatina 344<\/a> as the antagonist arm allows direct quantification of myostatin\/antagonist binding stoichiometry and rescue of GDF-8-induced atrophy in study models.<\/li>\n<\/ul>\n<p>For broader context on where GDF-8 fits within the anabolic \/ muscle-studies landscape, see <a href=\"https:\/\/medsbase.com\/pt-pt\/follistatin-344\/\">Follistatina 344<\/a> como o antagonista can\u00f3nico da miostatina, <a href=\"https:\/\/medsbase.com\/pt-pt\/igf-1-lr3\/\">IGF-1 LR3<\/a> para o bra\u00e7o anab\u00f3lico de via oposta (agonismo direto do IGF-1R), e <a href=\"https:\/\/medsbase.com\/pt-pt\/tb-500\/\">TB-500<\/a> for systemic muscle and tissue recovery. Browse the full <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para encontrar compostos relacionados. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks recombinant GDF-8 (Myostatin) in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 binding assays, atrophy-induction protocols, antagonist validation<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>GDF-8 is a ~25.8\u00a0kDa recombinant homodimeric protein supplied at \u226595% HPLC purity. The 1\u00a0mg vial format covers the typical dose range: nanomolar working concentrations for in-vitro binding and reporter-cell assays consume small fractions of a vial; in-vivo administration in rodent models uses microgram-per-injection doses that consume more vial per protocol. <\/p>\n<h2>Como Compara \u2014 GDF-8 (Miostatina) vs Follistatina 344<\/h2>\n<p>O GDF-8 recombinante e <a href=\"https:\/\/medsbase.com\/pt-pt\/follistatin-344\/\">Follistatina 344<\/a> are an inverse-pharmacology pair: GDF-8 is the ligand and Follistatin 344 is the high-affinity binding protein that sequesters it. They are routinely paired in studies because the antagonist&#8217;s function can only be quantified against the ligand. The relationship parallels other well-known inverse pairs in pharmacology (e.g., agonist + antagonist of the same receptor) but at the ligand-binding-protein level rather than the receptor level. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">GDF-8 (Miosstatina)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Follistatina 344<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Papel na biologia muscular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ligando atr\u00f3fico (o trav\u00e3o)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Prote\u00edna de liga\u00e7\u00e3o antagonista (removedor de trav\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Forma ativa<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Homod\u00edmero de 109 aa (~25,8 kDa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Glicoprote\u00edna monom\u00e9rica de 344 aa (~37 kDa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Recetor ou alvo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">ActRIIB (recetor de activina tipo IIB)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sequestra miostatina\/activina (sem recetor; liga\u00e7\u00e3o direta ao ligando)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Sinaliza\u00e7\u00e3o a jusante<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ativa Smad2\/Smad3, atrogenes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bloqueia a ativa\u00e7\u00e3o de Smad atrav\u00e9s da remo\u00e7\u00e3o do ligando<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Primary studies role<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ferramenta para induzir\/sondar o fen\u00f3tipo de atrofia<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ferramenta para reverter\/prevenir a atrofia<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013100 ng\/mL in vitro; 0,1\u201310 mcg in vivo<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013100 mcg in vivo por dose<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Emparelhamento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Utilizado em conjunto com a follistatina 344 para estequiometria de liga\u00e7\u00e3o<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Utilizado em conjunto com o GDF-8 para validar a atividade antagonista<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For muscle-studies design, the pair is used together in three principal ways: (1) binding-affinity measurement (surface plasmon resonance, ELISA, isothermal titration calorimetry) of follistatin\u2013myostatin interaction; (2) cell-based atrophy\/rescue assays where GDF-8 induces myotube atrophy and follistatin co-treatment is tested for rescue; and (3) in-vivo validation where GDF-8 amplifies a wasting phenotype that follistatin co-administration attenuates. The two proteins are mechanistically complementary and rarely studied in isolation. <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazenar os frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para stock de trabalho a curto prazo. Para armazenamento a longo prazo sem abertura, congelar a \u221220 \u00b0C. O GDF-8 liofilizado \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o at\u00e9 12 meses e a \u221220 \u00b0C at\u00e9 24 meses \u2014 um pouco menos do que os pequenos p\u00e9ptidos sint\u00e9ticos, uma vez que o d\u00edmero recombinante maior, ligado por dissulfureto, \u00e9 mais suscet\u00edvel a desdobramento incorreto e agrega\u00e7\u00e3o ao longo do tempo. Evitar ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o no p\u00f3 liofilizado. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injetar \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o composto liofilizado). Para um frasco de 1\u00a0mg, 1,0\u00a0mL de \u00e1gua bacteriost\u00e1tica produz uma concentra\u00e7\u00e3o de trabalho de 1\u00a0mg\/mL. Agitar suavemente \u2014 n\u00e3o <strong>n\u00e3o<\/strong> armazenar refrigerado a 2\u20138 \u00b0C e utilizar no prazo de 30 dias para uma estabilidade \u00f3tima. N\u00e3o congelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 as prote\u00ednas d\u00edmeras recombinantes s\u00e3o particularmente sens\u00edveis \u00e0 desnatura\u00e7\u00e3o por congela\u00e7\u00e3o-descongela\u00e7\u00e3o, o que produz agrega\u00e7\u00e3o e perda de atividade de liga\u00e7\u00e3o ao recetor. Descartar qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. Para ensaios de afinidade de liga\u00e7\u00e3o que requerem uma calibra\u00e7\u00e3o rigorosa da resposta \u00e0 dose, utilizar solu\u00e7\u00e3o rec\u00e9m-reconstitu\u00edda no prazo de 7 dias para obter os resultados mais reprodut\u00edveis. <strong>Ap\u00f3s reconstitui\u00e7\u00e3o:<\/strong> armazenar no frigor\u00edfico a 2\u20138 \u00b0C e utilizar no prazo de 30 dias para uma estabilidade \u00f3tima. N\u00e3o congelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 as prote\u00ednas d\u00edmeras recombinantes s\u00e3o particularmente sens\u00edveis \u00e0 desnatura\u00e7\u00e3o por congela\u00e7\u00e3o-descongela\u00e7\u00e3o, o que provoca agrega\u00e7\u00e3o e perda de atividade de liga\u00e7\u00e3o ao recetor. Descartar qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou altera\u00e7\u00e3o de cor. Para ensaios de afinidade de liga\u00e7\u00e3o que requeiram uma calibra\u00e7\u00e3o rigorosa da resposta \u00e0 dose, utilizar a solu\u00e7\u00e3o reconstitu\u00edda no prazo de 7 dias para obter os resultados mais reprodut\u00edveis. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is GDF-8 (Myostatin) used for in studies?<\/h3>\n<p>Recombinant GDF-8 is used in clinical studies as the canonical agonist of the myostatin pathway \u2014 it is the experimental tool for inducing reproducible muscle atrophy phenotypes, characterising Smad2\/Smad3 signalling, validating myostatin antagonists (including <a href=\"https:\/\/medsbase.com\/pt-pt\/follistatin-344\/\">Follistatina 344<\/a> and ActRIIB-Fc fusion proteins), and quantifying binding stoichiometry in pharmacology assays. It is not used to &#8220;improve&#8221; anything in study models \u2014 it is the negative regulator that users want to understand and ultimately inhibit. The pharmaceutical-grade GDF-8 sold here is <strong>n\u00e3o<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Em que \u00e9 que o GDF-8 difere da Follistatin 344?<\/h3>\n<p>The two are an inverse-pharmacology pair. GDF-8 is the active myostatin ligand \u2014 the brake on muscle growth that drives atrophy via Smad2\/Smad3 signalling. Follistatin 344 is a high-affinity binding protein that sequesters GDF-8 and activin, removing them from receptor availability. In study models, GDF-8 induces or amplifies the atrophy phenotype and follistatin 344 rescues it. The two are routinely paired in binding-affinity assays, cell-based rescue assays, and in-vivo validation studies of myostatin-pathway antagonists. <\/p>\n<h3>Em que \u00e9 que o GDF-8 difere do GDF-11?<\/h3>\n<p>GDF-8 (myostatin) and GDF-11 share approximately 90% amino-acid identity in the mature domain and bind the same ActRIIB receptor with comparable affinity. The functional roles are partially overlapping but distinct in tissue distribution: GDF-8 is predominantly expressed in skeletal muscle and is the dominant regulator of muscle mass; GDF-11 is more broadly expressed and is studied in cardiac, neural, and hematopoietic contexts. The close sequence similarity makes selective antagonist development a major focus of current studies. <\/p>\n<h3>What is the typical GDF-8 dose?<\/h3>\n<p>Os protocolos pr\u00e9-cl\u00ednicos publicados utilizam tipicamente concentra\u00e7\u00f5es de trabalho de 10\u2013100 ng\/mL para experi\u00eancias de cultura de c\u00e9lulas in vitro (ensaios de atrofia de miotubos, ensaios com c\u00e9lulas rep\u00f3rter, estudos de liga\u00e7\u00e3o), e 0,1\u201310 mcg por administra\u00e7\u00e3o para protocolos de indu\u00e7\u00e3o de atrofia in vivo em roedores. Um frasco de 1 mg reconstitu\u00eddo com 1,0 mL de \u00e1gua bacteriost\u00e1tica produz 1 mg\/mL \u2014 a dilui\u00e7\u00e3o em PBS ou meio de cultura fornece solu\u00e7\u00f5es de trabalho nanomolares para uso in vitro. <\/p>\n<h3>N\u00e3o. O GDF-8\/miostatina n\u00e3o \u00e9 aprovado pela FDA, EMA, MHRA ou qualquer outro regulador importante para uso terap\u00eautico humano. A investiga\u00e7\u00e3o da via da miostatina produziu antagonistas em fase cl\u00ednica (anticorpos anti-miostatina, ActRIIB-Fc sol\u00favel, terapia g\u00e9nica com follistatina), alguns dos quais chegaram a ensaios em fase avan\u00e7ada para distrofia muscular e sarcopenia, mas o GDF-8 recombinante em si n\u00e3o \u00e9 um terap\u00eautico. Todo o GDF-8 vendido por fornecedores apenas para uso em investiga\u00e7\u00e3o destina-se a investiga\u00e7\u00e3o laboratorial e n\u00e3o deve ser administrado a humanos.<\/h3>\n<p>No. GDF-8 \/ myostatin is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Myostatin pathway has produced clinical-stage antagonists (anti-myostatin antibodies, soluble ActRIIB-Fc, follistatin gene therapy), some of which have reached late-stage trials for muscular dystrophy and sarcopenia, but recombinant GDF-8 itself is not a therapeutic. <\/p>\n<h3>Como deve ser armazenado o GDF-8?<\/h3>\n<p>Viais liofilizados: refrigerados a 2\u20138 \u00b0C para stock de trabalho a curto prazo, ou \u221220 \u00b0C para armazenamento a longo prazo de viais n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, utilizar no prazo de 30 dias para protocolos gerais ou no prazo de 7 dias para ensaios de afinidade de liga\u00e7\u00e3o que requeiram calibra\u00e7\u00e3o rigorosa. N\u00e3o congelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 as prote\u00ednas dim\u00e9ricas recombinantes s\u00e3o particularmente sens\u00edveis \u00e0 desnatura\u00e7\u00e3o por congela\u00e7\u00e3o-descongela\u00e7\u00e3o. Proteger sempre da luz direta. A prote\u00edna transportadora (BSA a 0,1%) \u00e9 recomendada para dilui\u00e7\u00f5es de trabalho abaixo de 100 mcg\/mL. <\/p>\n<h3>Como reconstituir o GDF-8?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o liofilizado), agite suavemente e aguarde 5 a 10 minutos para dissolu\u00e7\u00e3o completa. N\u00e3o <strong>n\u00e3o<\/strong> Agite o frasco vigorosamente \u2014 uma agita\u00e7\u00e3o excessiva pode perturbar a liga\u00e7\u00e3o dissulfureto intermolecular e degradar a atividade. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 l\u00edmpida e incolor, sem part\u00edculas vis\u00edveis. Para um frasco de 1 mg + 1,0 mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 1 mg\/mL. <\/p>\n<h3>Por que \u00e9 que a especifica\u00e7\u00e3o de pureza \u00e9 de 95% em vez de 99%?<\/h3>\n<p>Recombinant proteins like GDF-8 cannot achieve the \u226599% HPLC purity standard typical of small synthetic peptides because of inherent heterogeneity in any recombinant expression system \u2014 different folding intermediates and disulfide-isomer forms appear as related peaks on HPLC that are not impurities but isoforms of the target protein. \u226595% HPLC purity is the standard pharmaceutical-grade specification for GDF-8 and similar recombinant disulfide-linked dimer proteins. SDS-PAGE typically shows the expected ~25.8\u00a0kDa band under non-reducing conditions and ~12.9\u00a0kDa monomer under reducing conditions. <\/p>\n<h3>Que dosagens est\u00e3o dispon\u00edveis na MedsBase?<\/h3>\n<p>MedsBase carries recombinant GDF-8 (Myostatin) in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at \u226595% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Can GDF-8 and Follistatin 344 be paired in studies?<\/h3>\n<p>Yes \u2014 this is the canonical use case. The two are routinely paired in three principal ways: (1) binding-affinity measurement via SPR, ELISA, or ITC of the follistatin\u2013myostatin interaction; (2) cell-based atrophy\/rescue assays where GDF-8 induces myotube atrophy and follistatin co-treatment rescues; and (3) in-vivo studies where GDF-8 amplifies a wasting phenotype that follistatin co-administration attenuates. The inverse-pharmacology pairing is foundational to myostatin-axis studies design. <\/p>\n<h3>Does GDF-8 cause side reported effects?<\/h3>\n<p>The principal on-target effect of recombinant GDF-8 in study models is muscle atrophy \u2014 this is the intended pharmacological action, not a side effect. Off-target findings include modest effects on cardiac and adipose tissues consistent with the lower-level expression of ActRIIB in those compartments. At very high doses, broader TGF-\u03b2-superfamily-related effects on fibrosis and inflammation can be observed, attributable to receptor cross-talk with activin and GDF-11 pathways. <\/p>\n<h3>Qual \u00e9 a meia-vida do GDF-8?<\/h3>\n<p>In preclinical studies, recombinant mature GDF-8 has a plasma half-life of approximately 2\u20134 hours following intravenous administration. Endogenously, mature myostatin circulates bound to its own prodomain (latent complex) and to follistatin \/ other binding proteins, which dramatically extends the effective tissue half-life. For protocols, the recombinant active dimer is administered without the prodomain to deliver &#8220;free&#8221; myostatin to the ActRIIB receptor. <\/p>\n<h3>Por que foi o GDF-8 originalmente descoberto?<\/h3>\n<p>O GDF-8 foi identificado por McPherron, Lawler e Lee na Johns Hopkins (Nature 1997) atrav\u00e9s de uma estrat\u00e9gia de rastreio por PCR degenerado concebida para encontrar novos membros da superfam\u00edlia TGF-\u03b2. A perturba\u00e7\u00e3o direcionada em ratos produziu animais com uma massa muscular esquel\u00e9tica duas a tr\u00eas vezes maior do que os controlos do tipo selvagem \u2014 um fen\u00f3tipo surpreendentemente claro que estabeleceu imediatamente a miostatina como o principal regulador fisiol\u00f3gico negativo do crescimento muscular. A liga\u00e7\u00e3o aos fen\u00f3tipos de \u201cdupla-muscula\u00e7\u00e3o\u201d que ocorrem naturalmente no gado Belgian Blue e nos c\u00e3es Whippet foi estabelecida em meses, e um caso de muta\u00e7\u00e3o humana no MSTN foi publicado no NEJM em 2004. <\/p>\n<h3>How long does GDF-8 take to show effects in preclinical studies?<\/h3>\n<p>Os efeitos in vitro na fosforila\u00e7\u00e3o de Smad2\/Smad3 s\u00e3o detet\u00e1veis minutos ap\u00f3s a exposi\u00e7\u00e3o celular. A atrofia de miotubos em ensaios baseados em c\u00e9lulas \u00e9 mensur\u00e1vel em 24\u201372 horas. Os fen\u00f3tipos de atrofia in vivo em modelos de roedores desenvolvem-se ao longo de 1\u20134 semanas de administra\u00e7\u00e3o regular, com cin\u00e9ticas que dependem da dose, da via de administra\u00e7\u00e3o e da linha de base de massa muscular do organismo modelo. <\/p>\n<h3>Posso encomendar GDF-8 para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia GDF-8 para todo o mundo a partir da nossa rede dedicada de envio de p\u00e9ptidos. As encomendas exclusivas de p\u00e9ptidos qualificam-se para o nosso servi\u00e7o de envio de p\u00e9ptidos aut\u00f3nomo. Todas as encomendas s\u00e3o enviadas em embalagens com controlo de temperatura, com rastreio completo e est\u00e3o cobertas pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Garantia de Reenvio<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Anabolic, Muscle, and Growth-Axis Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/follistatin-344\/\"><strong>Follistatina 344<\/strong><\/a> \u2014 Prote\u00edna de liga\u00e7\u00e3o antagonista da miostatina\/activina \u2014 o par de farmacologia inversa do GDF-8<\/li>\n<li><a href=\"\/pt-pt\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 An\u00e1logo recombinante de IGF-1 com arginina longa \u2014 est\u00edmulo anab\u00f3lico via oposta atrav\u00e9s do IGF-1R<\/li>\n<li><a href=\"\/pt-pt\/tb-500\/\"><strong>TB-500 (Thymosin Beta-4)<\/strong><\/a> \u2014 Systemic healing fragment \u2014 muscle and cardiac recovery<\/li>\n<li><a href=\"\/pt-pt\/cjc-1295-with-dac\/\"><strong>CJC-1295 com DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 growth hormone axis support<\/li>\n<li><a href=\"\/pt-pt\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Shorter-acting GHRH(1-29) analog \u2014 natural GH-pulse support<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore a via da miostatina<\/strong><\/p>\n<p style=\"margin: 0;\">Explore a gama completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, com o par de farmacologia inversa <a href=\"https:\/\/medsbase.com\/pt-pt\/follistatin-344\/\">Follistatina 344<\/a> as the myostatin antagonist for pathway-rescue studies, <a href=\"https:\/\/medsbase.com\/pt-pt\/igf-1-lr3\/\">IGF-1 LR3<\/a> for direct IGF-receptor anabolic studies, and <a href=\"https:\/\/medsbase.com\/pt-pt\/tb-500\/\">TB-500<\/a> for systemic muscle and tissue recovery.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Homod\u00edmero ativo de miostatina recombinante de 25,8 kDa<br \/>\n\u2705 Ligando atr\u00f3fico can\u00f3nico da superfam\u00edlia TGF-\u03b2<br \/>\n\u2705 Par de farmacologia inversa com Follistatin 344<br \/>\n\u2705 Agonista da via ActRIIB\/Smad2\/Smad3<br \/>\n\u2705 Pureza \u226595% por HPLC, COA dispon\u00edvel mediante pedido<\/p>\n<p><strong>GDF-8 (Miosstatina)<\/strong> \u00e9 uma prote\u00edna recombinante.<\/p>","protected":false},"featured_media":70950,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6279,6278,5441],"class_list":["post-70729","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-gdf-8","product_tag-myostatin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/70729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=70729"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/70950"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=70729"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=70729"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=70729"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=70729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}